Skip to main content
SpringerLink
Log in

Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer

  • Chapter
  • First Online:
Gastrointestinal Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR))

  • 1229 Accesses

Abstract

The management of borderline resectable cancer requires multi-disciplinary care including state-of-the-art radiographic imaging, combination treatment planning with medical oncology and radiation oncology, and technical surgical expertise combining gastrointestinal and vascular surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abbott DE, Baker MS et al (2010) Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol 101(4):315–320

    Article  CAS  PubMed  Google Scholar 

  2. Assifi MM, Lu X et al (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150(3):466–473

    Article  PubMed  PubMed Central  Google Scholar 

  3. Banz VM, Croagh D et al (2012) Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. Euro J Surg Oncol (EJSO) 38(1):72–79

    Article  CAS  Google Scholar 

  4. Bockhorn M, Uzunoglu FG et al (2014) Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS). Surgery 155(6):977–988

    Article  PubMed  Google Scholar 

  5. Callery MP, Chang KJ et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16(7):1727–1733

    Article  PubMed  Google Scholar 

  6. Castleberry AW, White RR et al (2012) The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American college of surgeons national surgical quality improvement program database. Ann Surg Oncol 19(13):4068–4077

    Article  PubMed  Google Scholar 

  7. Corsini MM, Miller RC et al (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo clinic experience (1975–2005). J Clin Oncol 26(21):3511–3516

    Article  PubMed  Google Scholar 

  8. Ferrone CR, Marchegiani G et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gillen S, Schuster T et al (2010) Preoperative/Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267

    Article  PubMed  PubMed Central  Google Scholar 

  10. Herman JM, Swartz MJ et al (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins hospital. J Clin Oncol 26(21):3503–3510

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hsu CC, Herman JM et al (2010) Adjuvant Chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins hospital—mayo clinic collaborative study. Ann Surg Oncol 17(4):981–990

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kantor O, Talamonti M et al (2015) 864 A graded evaluation of outcomes following pancreaticoduodenectomy with major vascular resection in pancreatic cancer: major vascular resection is associated with severe adverse postoperative outcome and early recurrence. Gastroenterology 148(4):S–1121

    Google Scholar 

  13. Katz MHG, Lee JE et al (2012) Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg 215(2):e11–e18

    Article  PubMed  PubMed Central  Google Scholar 

  14. Katz MHG, Pisters PWT et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833–846

    Article  PubMed  Google Scholar 

  15. Kim EJ, Ben-Josef E et al (2013) A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 119(15):2692–2700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Landry J, Catalano PJ et al (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101(7):587–592

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Laurence JM, Tran PD et al (2011) A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 15(11):2059–2069

    Article  PubMed  Google Scholar 

  18. Marti JL, Hochster HS et al (2008) Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 15(12):3521–3531

    Article  PubMed  Google Scholar 

  19. McClaine RJ, Lowy AM et al (2010) Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB 12(1):73–79

    Article  PubMed  PubMed Central  Google Scholar 

  20. Neoptolemos JP, Stocken DD et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA 304(10):1073

    Article  CAS  PubMed  Google Scholar 

  21. Neoptolemos JP, Stocken DD et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210

    Article  CAS  PubMed  Google Scholar 

  22. Oettle H, Neuhaus P et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA 310(14):1473

    Article  CAS  PubMed  Google Scholar 

  23. OʼReilly EM, Perelshteyn A et al (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260(1):142–148

    Article  PubMed  PubMed Central  Google Scholar 

  24. Patel M, Hoffe S et al (2011) Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 104(2):155–161

    Article  PubMed  PubMed Central  Google Scholar 

  25. Paulson AS, Tran Cao HS et al (2013) Therapeutic advances in pancreatic cancer. Gastroenterology 144(6):1316–1326

    Article  CAS  PubMed  Google Scholar 

  26. Qiu H, Wild AT et al (2012) Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol 104(2):167–172

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ravikumar R, Sabin C et al (2014) Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg 218(3):401–411

    Article  PubMed  Google Scholar 

  28. Regine WF, Winter KA et al (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. intergroup/RTOG 9704 Phase III Trial. Ann Surg Oncol 18(5):1319–1326

    Article  PubMed  PubMed Central  Google Scholar 

  29. Schnelldorfer T, Ware AL et al (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma. Ann Surg 247(3):456–462

    Article  PubMed  Google Scholar 

  30. Siddiqui AA, Kowalski TE et al (2013) EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. Gastrointest Endosc 77(4):669–670

    Article  PubMed  Google Scholar 

  31. Siegel R, Ma J et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29

    Article  PubMed  Google Scholar 

  32. Sohn T, Yeo C et al (2000) Resected adenocarcinoma of the pancreas? 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579

    Article  CAS  PubMed  Google Scholar 

  33. Stokes JB, Nolan NJ et al (2011) Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 18(3):619–627

    Article  PubMed  Google Scholar 

  34. Tamm EP, Balachandran A et al (2012) Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 50(3):407–428

    Article  PubMed  Google Scholar 

  35. Tempero MA, Malafa MP et al (2014) Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12(8):1083–1093

    CAS  PubMed  Google Scholar 

  36. Varadhachary GR, Tamm EP et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035–1046

    Article  PubMed  Google Scholar 

  37. Vauthey J-N, Dixon (2009) AHPBA/SSO/SSAT Consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol 16(7):1725–1726

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Chicago Pritzker School of Medicine, Chicago, IL, USA

    Mark S. Talamonti

  2. Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

    Mark S. Talamonti

Authors
  1. Mark S. Talamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark S. Talamonti .

Editor information

Editors and Affiliations

  1. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    David Bentrem

  2. Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA

    Al B. Benson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Talamonti, M.S. (2016). Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. In: Bentrem, D., Benson, A. (eds) Gastrointestinal Malignancies. Cancer Treatment and Research. Springer, Cham. https://doi.org/10.1007/978-3-319-34244-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34244-3_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34242-9

  • Online ISBN: 978-3-319-34244-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation